DURHAM, N.C., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the Company will host a presentation to shareholders on Wednesday, September 15, 2010 at 7:00 PM CEDT at the Hilton Zurich Airport Hotel. The presentation will be in (Swiss) German language and the content will be the same as at the Rodman & Renshaw Conference the day before.
In addition, Oxygen Biotherapeutics Chairman and Chief Executive Officer Chris Stern will present at the 10th Annual Biotech Forum at the Radisson Blu Hotel, Zurich Airport on September 29-30, 2010. His presentation will occur at 2:45 PM CEDT on September 29, 2010.
Stern will discuss the Company's strategy, recently commercialized DERMACTYE® skin care products, and its topical and clinical research and development programs.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte® that is being formulated for both topical and intravenous delivery. In April, the company launched its first cosmetic product, DERMACYTE Oxygen Concentrate and in August it introduced DERMACYTE Eye Oxygenating Complex. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, and topical wound healing. More information is available at www.oxybiomed.com, and www.buydermacyte.com .
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the DERMACYTE product line and the timing of the introduction of those new products. Matters beyond the company's control could lead to delays in the new product introductions and customer acceptance of these new products. Furthermore, there can be no assurance that such plans will lead to meaningful sales of DERMACYTE or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation, or sale is unlawful.